- Home
- ALEC vs ABEO Comparison
ALEC vs ABEO Comparison
Compare ALEC & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALEC | ABEO |
|---|---|---|
| Founded | 2013 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.2M | 307.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ALEC | ABEO |
|---|---|---|
| Price | $2.18 | $5.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $4.83 | ★ $20.00 |
| AVG Volume (30 Days) | 437.9K | ★ 906.1K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | ★ $21,045,000.00 | $2,998,000.00 |
| Revenue This Year | $2.03 | $1,024.31 |
| Revenue Next Year | $29.87 | $145.42 |
| P/E Ratio | ★ N/A | $5.82 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $1.01 | $4.00 |
| 52 Week High | $3.40 | $7.54 |
Technical Indicators
Market Signals| Indicator | ALEC | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 42.98 | 56.57 |
| Support Level | $1.89 | $5.24 |
| Resistance Level | $2.57 | $7.54 |
| Average True Range (ATR) | 0.16 | 0.26 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 24.46 | 54.44 |
Price Performance
Historical ComparisonAbout ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.